

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
2503-1033

SERIAL NO.
10/009,501

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

APPLICANT
Josee GOLAY et al.

FILING DATE
May 6, 2002

GROUP
1644

37 CFR 1.98(b)

U.S. PATENT DOCUMENTS

		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
	AC						
	AD						

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

AE	McLaughlin, Peter et al., "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program", <u>Journal of Clinical Oncology</u> , Vol. 16, pp. 2825-2833. XP-002149247
AF	
AG	
AH	
AI	
AJ	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

